Abstract
Breast cancer is a global health threat and cases diagnosed in women during the years after childbirth, or postpartum breast cancers (PPBCs), have high risk for metastasis. In preclinical murine models, semaphorin 7a (SEMA7A) drives the metastatic potential of postpartum mammary tumors. Thus, we hypothesize that SEMA7A may drive metastasis of PPBC in women. We report that SEMA7A protein expression is increased in PPBCs compared to their nulliparous counterparts in our University of Colorado cohort. Additionally, tumors from PPBC patients with involved lymph nodes and lymphovascular invasion were higher on average suggesting a potential role for SEMA7A as a prognostic biomarker. Consistent with this hypothesis we identify a level of SEMA7A expression in tumors that can predict for recurrence. We propose SEMA7A as a potential biomarker and therapeutic target for PPBC patients, who currently lack strong predictors of outcome and unique targeted therapy options.
Highlights
Breast cancer is a global health threat with an estimated 1.7 million cases annually
There were 47 nulliparous patients and 66 postpartum breast cancer (PPBC) patients that made it into the study (Supplementary Table 1)
We intentionally aimed for a similar (Fig. 2d; Supplemenatry Table 4). These results provide impetus for number of cases with and without disease recurrence between further exploration of semaphorin 7a (SEMA7A) and recurrance free survival (RFS)
Summary
Breast cancer is a global health threat with an estimated 1.7 million cases annually. RESULTS We included 113 cases from our Colorado Young Women’s Breast Cancer Cohort where we published an increased risk for metastatic recurrence in PPBC4.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
